Maxidex (dexamethasone eye drops, suspension) / Novartis, Harrow Health - LARVOL DELTA

Comparison of treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery. (clinicaltrialsregister.eu) - P4 | N=100 | Recruiting | Sponsor: UZ Leuven | Completed ➔ Recruiting

Enrollment open • Cataract • Ophthalmology

Ridge-Adjacent Laser With Imaging and Dexamethasone for Treatment of Retinopathy of Prematurity. (PubMed, J Pediatr Ophthalmol Strabismus) - "The intervention consisted of RALT with intraoperative wide-field imaging, and most patients also received postoperative dexamethasone eye drops...All eyes that did not have aggressive retinopathy of prematurity regressed after the RALT treatment. Further longitudinal studies are required to assess the long-term structural and functional outcomes."

Journal • Retinal Disorders • Retinopathy of Prematurity

Comment on "Efficacy of combined povidone-iodine 1% and dexamethasone 0.08% eye drops in treating post-viral corneal subepithelial infiltrates". (PubMed, Indian J Ophthalmol) - No abstract available

Journal

Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity: The DROPROP Randomized Clinical Trial. (PubMed, JAMA Pediatr) - "Although the analysis did not reach statistical significance, these findings suggest that topical dexamethasone may be a safe, noninvasive strategy to reduce the need for invasive treatment. euclinicaltrials.eu Identifier: 2023-505318-97-00."

Clinical • Journal • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity

EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jun 2026 ➔ Sep 2026

Minimal residual disease • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Jun 2029

Trial completion date • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology

Childhood ocular safety after postnatal exposure to topical dexamethasone during retinopathy of prematurity screening. (PubMed, Acta Ophthalmol) - "Preliminary data from extremely preterm infants exposed to off-label topical dexamethasone during ROP screening showed no clinically significant ocular adverse effects at standardized early childhood follow-up. Rates of strabismus and refractive errors were lower than expected. Larger studies with longer follow-up are needed to further assess ocular and systemic safety."

Journal • Glaucoma • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity • Strabismus

19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology

Anti-inflammatory effects of histamine receptor-4 (H4R) antagonists in a C57BL/6J model of experimental autoimmune uveitis (EAU). (ARVO 2026) - "On days 16-21, all mice with early EAU (4-5 per group) were treated daily with: vehicle control; topical dexamethasone (Maxidex; 5μl eye drops) as a treatment control; JNJ7777120 (50mg/kg) given intraperitoneally (ip) or ZPL101 (0.2, 2.0, 20 mg/kg, ip)...Comparing these two H4R antagonists in EAU, the anti-inflammatory effects suggest that differential mechanisms are involved in the suppression of retinal inflammation. Layman Abstract:The histamine receptor four is a promising modulator of the immune system; Various compounds are continuously produced/improved, trying to prove the concept that by the use of external agonists, antagonists or partial agonists of the receptor, we can moderate systemic inflammation more efficiently and without the topical, local or systemic side effects of already known immune modulators such as steroids."

Ocular Inflammation • Ophthalmology • Uveitis • CD4 • FOXP3

Does intracameral dexamethasone at the conclusion of routine cataract surgery decrease the incidence of post-operative complications? (ARVO 2026) - "Three surgeons used a postoperative regimen of immediate intracameral cefuroxime 1 mg plus topical dexamethasone 0.1% eye drops (Maxidex) four times daily for 3 weeks and ketorolac 0.5% (Acular) three times daily for 3 weeks. The findings suggest that the dexamethasone injection is safe and may offer benefits in the early recovery period, such as comfort and convenience, even if it does not change long-term outcomes. Larger studies on early patient experience may help determine whether it should become a routine part of cataract surgery care."

Surgery • Cataract • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Recruiting ➔ Active, not recruiting

Enrollment closed • Minimal residual disease • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Bilateral acanthamoeba keratitis following photorefractive keratectomy: a rare, severe complication. (PubMed, Int J Surg Case Rep) - "PRK with mitomycin C was performed in both eyes. After the procedure, the patient was treated with moxifloxacin-dexamethasone eye drops, lubricating eye drops, and therapeutic contact lenses...Cold water from the tap had been splashed directly into the patient's eyes in the first days following the procedure, which may have caused the infection. Preoperative counseling regarding contact with water is crucial in preventing this serious complication."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Pain

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=285 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

New P1/2 trial • Hematological Malignancies • Oncology • Pediatrics

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=455 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Aug 2027 ➔ Feb 2031 | Trial primary completion date: Aug 2027 ➔ Feb 2031

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology • Pediatrics

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=397 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | N=285 ➔ 397 | Trial completion date: Dec 2020 ➔ Jan 2022 | Trial primary completion date: Dec 2020 ➔ Jan 2022

Enrollment change • Trial completion date • Trial primary completion date • Pediatrics

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=460 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Jan 2022 ➔ Aug 2027 | Trial primary completion date: Jan 2022 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology • Pediatrics

Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=46 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

Acute posterior multifocal placoid pigment epitheliopathy complicated by a stroke, leading to the diagnoses of lupus anticoagulant and hypercysteinemia. (PubMed, J Fr Ophtalmol) - "APMPPE is a well-established disease, and neurological complications are rare. Cerebral vasculitis and strokes are the most commonly reported neurological lesions. The search for antiphospholipid syndrome and hypercysteinemia in the first-line work-up of APMPPE should be considered."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis

Engineering Mixed Micelle-Loaded Contact Lenses for Sustained Ocular Delivery of Dexamethasone: In Vitro and In Vivo Studies. (PubMed, ACS Appl Bio Mater) - "Conventional dexamethasone eye drops suffer from poor ocular bioavailability due to rapid tear turnover and limited corneal residence, necessitating frequent dosing and posing challenges in chronic ocular therapies...In conclusion, this dual-surfactant micelle platform markedly enhances the therapeutic potential of drug-eluting contact lenses, offering a safe, sustained, and patient-compliant alternative for managing ocular inflammation. These findings support further clinical translation of micelle-integrated lenses as next-generation ocular drug delivery systems."

Journal • Preclinical • Inflammation • Ocular Inflammation • IL6

COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: University of Nebraska | Trial primary completion date: Jan 2027 ➔ Jul 2027

Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (clinicaltrials.gov) - P2 | N=236 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Treating retinopathy of prematurity with dexamethasone eye drops: a difference-in-differences study in Sweden using register data. (PubMed, Ophthalmology) - "In this population of infants with severe ROP, the introduction of dexamethasone eye drops was associated with a significant reduction in the proportion of infants requiring traditional ROP treatments. A timely administration of low-dose dexamethasone eye drops may serve as a simple, cost-effective, and noninvasive intervention to reduce one of the leading causes of severe visual impairment worldwide. Further studies are needed to confirm our findings."

Journal • Retinal Disorders • Retinopathy of Prematurity

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=46 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

The efficacy of combined povidone-iodine 1% and dexamethasone 0.08% prepared eye drops in treating post-viral corneal subepithelial infiltrates. (PubMed, Indian J Ophthalmol) - "Combined povidone-iodine 1% and dexamethasone 0.08% eye drops offer superior improvement in SEIs, BCVA, and symptom relief, with lower recurrence compared to individual treatments. These findings suggest a potential synergistic effect of combined treatment in managing SEIs."

Clinical • Journal • Allergy • Conjunctivitis • Dry Eye Disease • Endocrine Disorders • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology